Compare iShares Core High Dividend ETF (HDV) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Medtronic PLC — how do they compare? iShares Core High Dividend ETF trades at $29.08, while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Medtronic PLC pays a 3.22% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| HDV | MDT | |
|---|---|---|
52-Week High | $29.14 | $105.35 |
52-Week Low | $23.64 | $73.75 |
Market Cap | — | $114.45B |
Sector | — | Health |
Enterprise Value | — | $133.19B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.78, up 0.21% with a bullish technical signal. It yields approximately 3.1% from dividends, with recent payouts in June and July 2026. The ETF focuses on high-quality U.S. large-cap dividend stocks, outperforming the S&P 500 year-to-date by 9 percentage points. News highlights its appeal for retirement income and institutional buying, such as 180 Wealth Advisors increasing its stake by 386.2% in Q2 2026.
The outlook is positive due to strong dividend sustainability and defensive sector weighting, but risks include interest rate sensitivity and concentrated holdings. Analysts favor HDV for income-focused portfolios, citing its quality screening and lower volatility.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
